Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm (1)
Mandate

Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm

September 23, 2019 Capital Markets and Public M&A

Vinge advises Vicore Pharma Holding AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market.

The prospectus was published on 16 September 2019 and the trading on Nasdaq Stockholm will commence on 27 September 2019.

Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs in preclinical or clinical phase.

Vinge’s team has primarily consisted of Jesper Schönbeck, Nils Fredrik Dehlin, Astrid Isberg, Emelie Svanberg, Viktor Bergsten and Sofia Bergenstråhle.

Related

Vinge has advised Sluta Gräva in connection with its acquisition of Stavrex

 Vinge has advised Sluta Gräv, a portfolio company of Sobro, in connection with the acquisition of Stavrex. Together, the companies form the Nordic region’s leading supplier of ground screws, with the market’s broadest offering.
February 18, 2026

Vinge advises Stendörren in connection with issuance of subsequent green bonds

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of subsequent senior unsecured green bonds in an amount of SEK 300 million (within a framework of SEK 800 million).
February 18, 2026

Vinge advises DNB Carnegie in connection with a EUR 130 million bond issue to finance Incore Invest’s acquisition of CoreOrchestration

 Vinge has advised DNB Carnegie Investment Bank AB (publ), in its capacity as sole bookrunner, in connection with an issue of senior secured bonds of EUR 130 million under a framework of EUR 200 million.
February 16, 2026